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Abstract  
 
The objective was to examine duloxetine 60–120mg/day treatment for relapse prevention in adults 
with generalized anxiety disorder (GAD). Adult patients (N=887; mean age=43.3 years; 61.0% 
female) with DSM-IV-TR-defined GAD diagnosis were treated with duloxetine for 26 weeks. Patients 
who completed open-label phase and were treatment responders (≥50% reduction in Hamilton Anxiety 
Rating Scale total score to ≤11 and “much”/“very much improved” ratings for the last 2 visits of open-
label phase) were randomly assigned to receive duloxetine or placebo for a 26-week double-blind 
continuation phase. Relapse was defined as ≥2-point increase in illness severity ratings or by 
discontinuation due to lack of efficacy. During the double-blind phase, placebo-treated patients 
(N=201) relapsed more frequently (41.8%) than duloxetine-treated patients (13.7%, N=204, P≤0.001) 
and worsened on each outcome measure (P≤0.001, all comparisons). Duloxetine 60–120 mg/day 
treatment was efficacious and reduced risk of relapse in patients with GAD.   
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1. Introduction  
 
Generalized anxiety disorder (GAD) is recognized as a chronic anxiety disorder with a 
persistent, deleterious course and substantial social impairment, as observed within 
community and epidemiological studies (Wittchen and Hoyer, 2001; Wittchen and Jacobi, 
2005). Reflecting the persistence of GAD, the DSM-IV-TR diagnostic criteria for this 
disorder require excessive worry or anxiety that is difficult to control for at least 6 months 
(APA, 2000). Patients must also experience at least 3 of the following symptoms: restlessness, 
fatigue, difficulty concentrating, irritability, muscle tension, or sleep disturbance, for more 
days than not during this 6-month time frame. After the onset of GAD, the course may 
fluctuate in severity of symptoms, but impairment associated with GAD tends to persist, and 
spontaneous remission is rare (Yonkers et al., 1996). For example, in a naturalistic 
longitudinal study of anxiety patients (Harvard/Brown Anxiety Research Program), at the end 
of 12 years, the probability of recovery from an index episode of GAD was 58% and the 
probability of experiencing a recurrent episode for patients who had recovered was 45% 
(Bruce et al., 2005).  
 
In the context of persistence, long-term utility and tolerability must be considered when 
developing a treatment plan for GAD. Previously, benzodiazepines were the primary 
pharmacological intervention; however, concerns about abuse liability, development of 
tolerance, and loss of efficacy have reduced the usefulness of benzodiazepines for long-term 
illness management of chronic anxiety (Mahe and Balogh, 2000). In addition, the 
understanding that the neurobiology of GAD involves multiple neurotransmitter systems has 
shifted treatment recommendations to the use of selective serotonin reuptake inhibitors 
(SSRIs) and serotonergic noradrenergic reuptake inhibitors (SNRIs) as first-line 
pharmacological interventions (Goodman, 2004).  
 
Long-term treatment efficacy has been studied using double-blind, placebo-controlled trials, 
in which the therapy period has been extended to ≥12 weeks. Gelenberg et al. (2000) 
examined the efficacy of venlafaxine XR compared with placebo for a 6-month treatment 
phase and found venlafaxine treatment was associated with significantly greater improvement 
in anxiety at study end point compared with placebo treatment. Due to concerns about study 
attrition and the use of placebo long-term, an alternative study design that has been used for 
long-term efficacy is the randomized withdrawal design that is also termed relapse prevention. 
In this design, patients are initially treated using open-label active treatment; responders are 
then entered into a double-blind continuation phase where they are randomly assigned to 
maintain active treatment or switch to placebo and then followed for relapse. The randomized 
withdrawal design has been used for controlled studies of paroxetine and escitalopram 
(SSRIs) and venlafaxine (SNRI). Overall, patients treated with the SSRI treatments showed 
less risk of relapse compared with placebo for treatment periods of 24 to 76 weeks, but this 
finding was not observed with venlafaxine (Allgulander et al., 2006; Stocchi et al., 2003; 
Hackett et al., 2000).  
 
Duloxetine, an SNRI, was recently approved for the treatment of GAD in adults based on 3 
independent, placebo-controlled, acute-therapy (9–10 weeks) trials (Rynn et al., 2008; 
Koponen et al., 2007; Hartford et al., 2007). The objective of the present study was to 
examine the long-term efficacy of duloxetine 60 mg to 120 mg once daily for the prevention 
of relapse in patients with GAD who responded therapeutically to an initial 6-month course of 
duloxetine treatment.  
 
2. Experimental procedures  
 
2.1. Study design  
 
The study design was a randomized relapse prevention study with a 26-week open-label, 
flexible-dose acute-therapy phase with duloxetine followed by a 26-week double-blind, 
placebo-controlled continuation therapy phase; the study also had a screening and a 3-week 
taper/follow-up therapy phase. In the open-label phase, patients were started with duloxetine 
30 mg/day for 1 week that was then increased to 60 mg/day. After 4 weeks of treatment, doses 
were managed flexibly based on the physician's judgment; however, if a patient's Clinical 
Global Impressions Improvement (CGI-I; Guy, 1976a) rating was minimal improvement, no 
change, or worse after 4 weeks, a 30-mg/day dose increase was required up to a maximum of 
120 mg/day. Patients could decrease dose if tolerability concerns arose; the minimum 
allowable dose was 60 mg, and dosage was stabilized after 8 weeks of treatment. During the 
open-label phase, patients were assessed monthly at weeks 8 through 20 and then biweekly at 
weeks 22, 24, and 26.  
 
Patients who completed the open-label phase and met response criteria were eligible for the 
double-blind continuation phase. Responder status was required for the last 2 consecutive 
visits of the open-label trial and was defined as a ≥50% reduction in Hamilton Anxiety Rating 
Scale (HAMA; Hamilton, 1959) total score from baseline to a score ≤11 and a CGI-I rating of 
“very much” or “much improved”. Nonresponders were discontinued from the study. 
Although the study design and protocol were blinded regarding the time of randomization 
(weeks 22 to 26), the actual double-blind assignment of treatment occurred at week 26 in a 
1:1 ratio and was administered via an interactive voice recognition system. Patients who were 
randomly assigned to placebo underwent a 2-week taper of study medication, while those 
assigned to duloxetine were continued at the same dose as their open-label phase treatment. 
All doses were taken once daily, and to maintain the blind, all patients received 4 capsules 
throughout the double-blind phase. After randomization at week 26, visits occurred at weeks 
28, 32, 36, 40, 44, 48, and 52.  
 
The study was implemented in accordance with the principles of Good Medical Practice and 
the Declaration of Helsinki (WMA, 2000). Each investigative site approved the protocols 
independently through external review boards, and all patients provided informed written 
consent. The blind regarding the onset of randomization to the double-blind phase was 
maintained by submission of a protocol supplement directly to the external review boards, 
independently of investigative sites.  
 
2.2. Patients  
 
Male and female patients aged ≥18 years were recruited globally from outpatient psychiatric 
clinics and university settings (28 sites throughout Austria, France, Germany, Portugal, and 
the Netherlands and 22 sites in the United States). Patients had to meet the Diagnostic and 
Statistical Manual of Mental Disorders, IV edition, text-revision criteria for GAD (DSM-IV-
TR; APA, 2000), which were assessed via the Mini International Neuropsychiatric Interview 
for the DSM (MINI; Sheehan et al., 1998) and confirmed by study psychiatrist. Patients' 
illness had to be at least moderately severe as indicated by a Clinical Global Impressions 
Severity (CGI-S; Guy, 1976a) rating of ≥4 (moderate), a Hospital Anxiety and Depression 
Scale (HADS; Zigmond and Snaith, 1983) anxiety subscale score ≥10, and a Covi Anxiety 
Scale (CAS; Lipman and Covi, 1976) score ≥9. To ensure predominance of anxiety 
symptoms, none of the 5 items on the Raskin Depression Rating scale (RDR; Raskin et al., 
1969) could be scored N3, and the CAS score had to be greater than the RDR total.  
 
Patients were not eligible to participate in the study if they met any of the following 
diagnoses: current or previous 6-month diagnosis of major depressive disorder, or substance 
abuse or dependence; a past year history of panic disorder, posttraumatic stress disorder, or an 
eating disorder; or a lifetime diagnosis of obsessive–compulsive disorder, bipolar affective 
disorder, psychosis, factitious disorder, or somatoform disorder. They were excluded if they 
were taking psychotropic medications within 7 days before baseline (14 days for 
benzodiazepines and 4 weeks for fluoxetine or a monoamine oxidase inhibitor), consuming 
excessive caffeine per investigator judgment, or had any medical condition that would 
contraindicate taking duloxetine. Women who were breastfeeding or pregnant were not 
allowed to participate, and women of childbearing potential were required to use reliable 
methods of birth control. Patients who had a prior treatment history with duloxetine or whose 
GAD had failed to respond to 2 adequate trials of pharmacological treatment per the treating 
physician were ineligible as well.  
 
 
2.3. Outcome measures  
 
The primary efficacy measure was the time to relapse during the 26- week double-blind 
continuation therapy phase. Relapse was defined as an increase in the CGI-S rating of at least 
2 points from randomization (end of open-label phase) to a score ≥4 (moderate) while 
meeting criteria for GAD confirmed by the MINI or by discontinuation due to lack of 
efficacy.  
 
The secondary efficacy measure was the HAMA total score, which was administered using 
the Structured Interview Guide for the HAMA version (SIGH-A; Shear et al., 2001). The 
HAMA is a clinician-rated instrument consisting of 14 items that are rated on a 0 (“not at all”) 
to4 (“very severe/disabling”) scale; higher total scores indicate greater distress and 
impairment. The SIGH-A version specifies instructions for administration and scoring based 
on frequency, severity, and impairment of symptoms and has been demonstrated to increase 
reliability (Shear et al., 2001). Study personnel involved in assessing patients were required to 
obtain sponsor approval, which was based on their demonstrating interviewing competence 
via mock interviews and scoring reliability via a videotaped interview. The intraclass 
correlation coefficient for the HAMA total score was 0.91 for the training tape and 0.87 for a 
recalibration tape during the study; both values indicate excellent interrater reliability.  
 
Additional outcome measures included the HAMA psychic factor score (sum items 1–6, 14) 
and the HAMA somatic factor scores (sum of items 7–13). Patients completed the 14-item 
HADS, which consists of separate subscales (7 items each) for anxiety and depression; higher 
scores indicate greater symptom frequency or distress. Overall improvement was rated by 
clinicians using the CGI-I and by the patients using the Patient Global Impressions of 
Improvement (PGI-I; Guy, 1976b). Ratings for these scales range from 1 to 7, in which lower 
scores indicate greater improvement. CGI-I and CGI-S ratings were required to be completed 
by a physician who had at least 1 year experience in the treatment of patients with anxiety 
disorders.  
 
Role functioning was assessed by the Sheehan Disability Scale (SDS; Sheehan, 1983), in 
which patients rated their degree of impairment using a 10-point scale from 0 (“none”) to 10 
(“extremely disabling”) for 3 life domains: work/school, social life, and family/ home 
responsibilities. The global functioning impairment score is the sum of the 3 items, and global 
scores N5 have been shown to indicate impairment associated with psychiatric illness (Leon 
et al., 1997). Patients' satisfaction with their lives and perceived health were measured by the 
Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF; 
Endicott et al., 1993) and the European Quality of Life: 5 Dimensions Visual Analogue Scale 
(EQ-5D VAS; EuroQol, 1990).  
 
Tolerability of study medication was assessed by spontaneously reported adverse events 
(AEs) and reasons for study discontinuation. At each visit, clinicians also completed the Beck 
Scale for Suicidal Ideation (BSSI; Beck et al., 1979), which has an initial screening question; 
positive responses to the screening are followed by detailed assessment of a patient's 
behaviors, attitudes, and plans to commit suicide. Although any positive score on this scale 
has been associated with increased risk for suicidal behaviors, a score of ≥6 has been used to 
denote at least moderate ideation and significant risk for suicidal behaviors (Sokero et al., 
2003). Vital signs were also collected at each visit.  
 
 
 
2.4. Statistical analyses  
 
The study sample size was targeted for 760 patients to obtain 90% power based on 
assumptions of 15% relapse rate in duloxetine, 30% relapse rate for placebo, a 52% 
discontinuation rate during the open-label phase, and a 2-sided log-rank test with á=0.05 
significance level. Values were defined for baseline (last nonmissing value for visits 1 and 2); 
open-label end point (last nonmissing value for weeks 1–26); double-blind baseline (last 
nonmissing value for weeks 1–26); and study end point (last observed nonmissing value for 
weeks 1–52). Treatment response was defined as a ≥50% reduction in Hamilton Anxiety 
Rating Scale total score from baseline to a score ≤11 and a CGI-I rating of “very much” or 
“much improved”. Remission was defined as a HAMA total score at end point ≤7.  
 
The primary efficacy analysis was time to relapse during the double-blind continuation phase. 
Patients who did not relapse were censored at study end point. Survival curves were 
constructed using the Kaplan–Meier product limit method and compared using a stratified 
log-rank test controlling for investigator. Relapse rates between groups were compared using 
a Cochran–Mantel–Haenzel test controlling for investigator and were based on the number of 
patients with a baseline and at least one nonmissing post-baseline observation.  
 
For the open-label phase, efficacy analyses were based on all patients enrolled into the 
duloxetine treatment. Mean changes between baseline to open-label study end point were 
analyzed using t-tests to determine if they were significantly different from zero. For the 
double-blind phase, efficacy analyses were based on the intent-to-treat sample, which 
consisted of all patients with a double-blind randomization observation and a 
postrandomization observation. An analysis-of-covariance (ANCOVA) model was used to 
compare treatment group differences from double-blind baseline to study end point on 
continuous variables with treatment and investigator as main effects, and the double-blind 
baseline score as the covariate. For the CGI and PGI improvement ratings, study end-point 
values were compared using an analysis of variance (ANOVA) with treatment and 
investigator as main effects. To examine changes across time, a repeated measures maximum 
likelihood-based mixed-effects model was used for the HAMA total score with fixed effects 
of treatment, investigator, visit, and treatment-by-visit interactions and covariates of the 
double-blind baseline score and baseline-by-visit interaction. All mean changes, unless 
otherwise noted, refer to least-squares means, which are adjusted for the model. Relapse and 
remission (HAMA total score ≤7 at end point) rates between treatment groups were compared 
using a Cochran–Mantel–Haenzel test controlling for investigator. For categorical safety 
variables frequencies between groups in the double-blind phase were compared using Fisher's 
exact test.  
 
3. Results  
 
3.1. Patient characteristics and disposition  
 
The study was conducted between January 2005 and March 2007. A total of 1132 patients 
were screened for the study, and 887 met inclusion/exclusion criteria and were enrolled into 
the open-label phase. As anticipated, 51.5% of the study participants discontinued during the 
6-month open-label phase (Fig. 1). The most frequent reasons for study discontinuation were 
adverse events (13.6%), subject decision (12.0%), or failure to meet responder criteria by end 
of the open-label phase (9.7%). Dose escalation did not occur for 148 patients (20.7%), 
whereas the dose for 299 patients (41.8%) was increased to 90 mg/day and for 268 patients 
(37.5%), to 120mg/day. The mean duration of study drug exposure for the open-label phase 
was 136.0 days (SD=70.1).  
 
At the double-blind baseline, there were no significant differences between patients randomly 
assigned to duloxetine (n=216) or placebo (n=213) in their demographics or illness 
characteristics (Table 1). The majority of the sample was female and Caucasian. The mean 
duration of study drug exposure during the double-blind phase was 156.1 days (SD=55.7) for 
duloxetinetreated patients and 125.3 days (SD=67.2) for placebo-treated patients (P≤0.001). 
Patients who were assigned to placebo were significantly more likely to withdraw from the 
continuation phase due to lack of efficacy than patients treated with duloxetine (31.0% vs 
9.7%, P≤0.001).  
 
3.2. Open-label treatment efficacy  
 
For patients who completed the open-label phase, 78.8% (n=533) of patients met the 
responder criteria and were eligible for randomization to the double-blind phase. Duloxetine 
treatment was associated with significant improvement on all secondary efficacy and patient 
functioning measures. Patients experienced improvements in their illness severity, as 
indicated by a mean decrease from baseline in HAMA total score of −14.9 (SD=10.1, 
P≤0.001, within subject) and in their role functioning. The mean SDS global functioning 
score at the open-label end point indicated minimal impairment (Table 2). In the intent-to-
treat sample, the remission rate at open-label end point was 44.3% (n=858).  
 
3.3. Double-blind continuation phase treatment efficacy  
 
Significantly more placebo-treated patients (n=84, N=201, 41.8%) met relapse criteria 
compared with duloxetine-treated patients (n=28, N=204, 13.7%; P≤0.001). Among patients 
who did relapse, duloxetine-treated patients had a longer time to relapse compared with 
patients who were switched to placebo (Fig. 2, log-rank test, P≤0.001). At week 28, which 
was the end of the medication taper for the placebo group, the number of patients who 
discontinued from the study was the same within the placebo and the duloxetine group (n=4).  
 
Patients who were continued with duloxetine treatment maintained the improvements that 
were demonstrated during the open-label phase. Patients who were switched to placebo 
significantly worsened on each of the secondary outcome measures, including the HAMA 
total score (Fig. 3), HAMA psychic factor score, HAMA somatic factor scores, and HADS 
anxiety subscale (all comparisons between duloxetine and placebo, P≤0.001, Table 2). The 
remission rate for duloxetine-treated patients at end point was 68.1% (n=145), which was 
significantly greater than the remission rate for placebo-treated patients (n=83, 39.3%, 
P≤0.001).  
 
With regard to functional impairment, patients treated with placebo during the double-blind 
phase also had a worsening of their role functioning in all 3 SDS domains of work/school, 
social life, and family/home management compared with patients who continued with 
duloxetine (P≤0.001; Table 2). By study end point, the mean SDS global functioning 
impairment score for the placebo group had significantly increased into the range indicating 
mild to moderate impairment (P≤0.001; Table 2). Patients in the placebo group were rated as 
overall less improved by both the CGI-I and PGI-I mean end-point scores compared with 
patients in the duloxetine group (P≤0.001, both comparisons). The switch to placebo was also 
associated with decreased life satisfaction and poorer perceived health, as measured by the 
mean changes in Q-LES-Q-SF and EQ-5D VAS scores (P≤0.001, all comparisons; Table 2) 
compared with patients who continued with duloxetine.  
 
3.4. Tolerability  
 
3.4.1. Open-label treatment phase  
 
During the open-label phase, 15 treatment-emergent AEs occurred at a frequency of ≥5%: 
nausea (28.3%), headache (18.7%), dry mouth (14.3%), diarrhea (14.2%), dizziness (13.4%), 
constipation (12.5%), fatigue (11.5%), hyperhidrosis (10.0%), insomnia (9.8%), somnolence 
(8.2%), decreased appetite (6.1%), upper respiratory tract infection (5.5%), decreased libido 
(5.4%), vomiting (5.4%), and nasopharyngitis (5.0%). Eighteen patients (2.0%) had a positive 
response to the initial screening questions of the BSSI during the open-label phase. At end 
point, these patients had a mean BSSI score of 5.7 (values observed ranged 0–19, SD=6.1), 
which did not differ significantly from their baseline mean value of 5.4 (values observed 
ranged 0–26; SD=6.6; P=0.84). Mean change from baseline to open-label end point was 2.2 
bpm (SD=10.3) for pulse rate (Pb0.001 within subject), 0.68 mm/Hg (SD=12.2) for systolic 
BP (P=0.104), and 1.1 mm/Hg (SD=8.7) for diastolic BP (Pb0.001).  
 
Most AEs were rated as mild to moderate in severity. Discontinuation from the study due to 
AEs occurred for 13.6% of patients (n=121), with nausea being the most frequent AE (n=11, 
1.2%). The remaining AEs that led to discontinuation were each cited at a frequency of 
b1.0%. Eleven patients experienced serious AEs (SAEs) that included acute alcoholic 
intoxication, alcohol dependency, anxiety, arrhythmia, cellulitis, cerebral hemorrhage 
(resulted in patient death), depression, diverticulitis, mania, nephrolithiasis, attempted suicide 
(2 patients), suicide (resulted in fatality), stress, and syncope. For the patient who died by 
cerebral hemorrhage, vital signs were normal at the visit prior to death; duloxetine dose was 
60 mg/ day, and concomitant medications included acetylsalicylic acid and ibuprofen. For the 
patient who died by suicide, the SSI score was 0 at the visit before death; duloxetine dose was 
60 mg/day, and concomitant medications were lercanidipine hydrochloride, elidiur, 
allopurinol, esomeprazole, and ferrous aminopropane dicarboxylate.  
 
3.4.2. Double-blind continuation phase  
 
During the double-blind continuation phase, placebo-treated patients experienced 
discontinuation-emergent AEs as the study medication was being withdrawn. Compared with 
patients in the duloxetine group, dizziness was the only AE to occur significantly more often 
in the placebo group (9.9% vs 3.7%, P≤0.05). No significant increases in pulse rate, diastolic 
BP, or systolic BP were observed during the double-blind phase in duloxetine-treated patients 
compared with placebo-treated patients.  
 
Most AE symptoms were rated mild to moderate in severity. Discontinuation from the study 
due to AEs occurred for 4 patients (1.9%) in the duloxetine group (acute bronchitis, 1; 
pregnancy, 2; epileptic seizure, 1) and for 2 patients in the placebo group (dizziness, 1; weight 
gain, 1) (P= 0.685). Combining the open-label and double-blind phases, the overall rate of 
discontinuation due to AE for duloxetine-treated patients was 125/887 (14.1%). During the 
double-blind phase, the SAEs within the duloxetine group were bronchitis, diarrhea, and 
worsening of GAD (1 patient each); within the placebo group, 1 patient had a fall with a 
ruptured tendon.  
 
 
4. Discussion  
 
The results of this study demonstrate long-term efficacy of duloxetine in the treatment of 
GAD in adults. For patients who initially responded to duloxetine treatment, continuation 
with duloxetine 60 mg to 120 mg once daily significantly reduced the risk of subsequent 
relapse, compared with placebo, during the study period of 6 months. When duloxetine-
treated patients with GAD were switched to placebo, their symptoms significantly worsened 
across illness severity and functional outcome measures, and these patients had 3 times the 
rate of relapse compared with patients who were continued on duloxetine (41.8% vs. 13.7%, 
respectively). Although placebo-treated patients underwent medication taper, the rate of 
relapse was not associated with the discontinuation period, and therefore likely reflects a 
return of an active disease state.  
 
The magnitude and risk of relapse following withdrawal of duloxetine were similar to rates 
observed in other relapse prevention studies. For patients who responded to escitalopram 
treatment after 12 weeks and were switched to placebo, the rate of relapse (defined as HAMA 
total score ≥15) was 56% compared with a rate of 19% for those who continued on 
escitalopram for another 24 to 76 weeks (Allgulander et al., 2006). Similarly, for patients who 
responded to an 8-week trial of paroxetine, double-blind randomization to either placebo or 
continued paroxetine for another 24 weeks resulted in relapse rates (defined as an increase in 
CGI-S ratings of ≥2 from randomization) of 39.9% and 10.9%, respectively (Stocchi et al., 
2003). On the other hand, another similarly designed study (8-week open-label/24-week 
double-blind) of venlafaxine extended-release did not find significant differences in relapse 
rates between those who were switched to placebo and those who continued active treatment 
(16% vs 12%, respectively) (Hackett et al., 2000). Nonetheless, notwithstanding the 
differences in design, duration, and definitions of response and relapse, the preponderance of 
evidence supports the conclusion that these pharmacological interventions continue to be 
efficacious during long-term treatment.  
 
Without a placebo control, the frequency of treatment-emergent AEs in the open-label phase 
cannot be definitively associated with duloxetine treatment. The suicide behaviors that 
occurred during the open-label phase of this trial were unexpected and have not been 
observed in the acute trials for GAD; a meta-analysis of controlled trials with duloxetine for 
major depressive disorder did not show increased risk for suicide behaviors and ideation 
(Acharya et al., 2007). On the other hand, suicide ideation and behaviors have been associated 
with generalized anxiety disorder in epidemiological and longitudinal studies (Sareen et al., 
2005; Boden et al., 2007). Overall, the number and type of the most frequent treatment-
emergent AEs were comparable with those observed in the placebo-controlled double-blind 
studies (i.e, approximately 12 treatment-emergent AEs, with nausea being the most frequent). 
A pooled analysis of the 3 acute trials showed a study discontinuation rate due to 
treatmentemergent AEs of 15.6% (Allgulander et al., 2007), which was slightly higher than 
the 14.1% rate observed within this 52-week study. Similarly, the mean changes in pulse rate 
and systolic BP were consistent with the cardiovascular profile of duloxetine (Thase et al., 
2005).  
 
One strength of the study design was the 6-month duration for the open-label phase, which 
allowed stabilization of response to duloxetine treatment; therefore, the recurrence of 
symptoms in the continuation phase is likely to reflect a recurrence of the illness rather than 
symptom fluctuation. However, the long duration of the study also created the logistical 
challenge of patient retention in the study. As anticipated, approximately half of the enrolled 
patients discontinued in the initial 6 months, with patient decision being one of the leading 
reasons for discontinuation. This rate of study completion in a sample of patients with GAD 
parallels rates of adherence to antidepressant treatment observed within naturalistic and claim-
based studies (McManus et al., 2004; Stein et al., 2006). Although patient adherence is related 
to multiple factors, patient's knowledge and perception of benefit are a key dimension 
(Wagner et al., 1996). Recognition that discontinuation resulted not only in a return of 
symptom severity, but diminished quality of life, therefore, may be informative to assist 
patients in adherence. Another strength of the study design was the use of stringent criteria for 
response and relapse to assure that the changes that occurred during the course of the study 
were clinically meaningful. In addition, patients were unaware of the exact timing of the 
potential withdrawal of medication, which may have helped to reduce patient's and clinician's 
expectancies as to the timing and likelihood of relapse.  
 
The results of the present study should also be evaluated in the context of a few limitations. 
As noted, attrition occurred throughout the study, which may limit the generalizability of the 
findings. Secondly, the patients were selected for having primary GAD without significant 
comorbidity. Because GAD is frequently comorbid with both anxiety and affective disorders, 
the findings may not generalize to the clinical patient who has substantial comorbidity among 
the different disorders.  
 
In summary, duloxetine 60 to 120 mg once daily was efficacious in attaining and continuing 
remission during the course of a year for patients with GAD. A frequent question for both 
patients and physicians in developing a treatment plan is what should be the optimal duration 
for continued treatment after a therapeutic response has been obtained. For many patients, the 
remission of symptoms may equate to the absence of a disease state and hence a propensity to 
discontinue treatment. Whereas the present study cannot describe the actual underlying state 
of pathology, the results suggest that additional 6-month treatment provided continued 
protective benefit. Therefore, physicians and patients should consider a chronic illness model 
for GAD as a reference point in developing their treatment plans (Keller, 2002).  
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